New Haven Pharmaceuticals, Inc.reports that the FDA has approved DURLAZA (aspirin) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack).

“We are very pleased to have received FDA approval … and we now look forward to making it available by prescription in the fourth quarter of 2015,” said Patrick Fourteau, CEO of New Haven Pharmaceuticals.